SENORES

- Concall Schedule - Concall Date: 02nd September 2026 - Concall Time: 11:00 AM (IST) Onwards - Hosted by: Elara Capital - Mode of Meeting: Physical at Mumbai

- Board meeting held on August 26, 2026. - Appointed Mrs. Shilpa Sharma as Company Secretary & Compliance Officer. - Appointed Mr. Viranchi Arvindbhai Shah as Non-Executive Additional Director (Independent Director). - Approved the Employee Stock Option Scheme 2026. - Approved incorporation of a Wholly Owned Subsidiary in Mexico and a Subsidiary in Canada for international expansion.

- The Board of Directors approved the appointment of Mrs. Shilpa Sharma as Company Secretary and Compliance Officer (KMP) w.e.f. August 26, 2026. - Approved the appointment of Mr. Viranchi Arvindbhai Shah as a Non-Executive Additional Director (Independent Director) w.e.f. August 26, 2026. - Approved the Senores Pharmaceuticals Employee Stock Option Scheme 2026, which covers 472,000 employee stock options (1% of existing equity on a fully diluted basis). - Approved the incorporation of a Wholly Owned Subsidiary (WOS) in Mexico (100% owned) for pharmaceutical product supply and distribution in Mexican and international markets. - Approved the incorporation of a Subsidiary Company in Canada (51% or more shareholding) for pharmaceutical product supply and distribution in the Canadian market.

- Board of Directors approved the appointment of Mrs. Shilpa Sharma as Company Secretary and Compliance Officer (KMP) w.e.f. August 26, 2026. - Board approved the appointment of Mr. Viranchi Arvindbhai Shah as Non-Executive Additional Director (Independent Director) w.e.f. August 26, 2026. - Approval for Senores Pharmaceuticals Employee Stock Option Scheme 2026 (ESOS 2026), covering 472,000 options (1% of existing equity). - Approved incorporation of a Wholly Owned Subsidiary (WOS) in Mexico for business and strategic objectives in Mexican and international markets. - Approved incorporation of a Subsidiary Company in Canada for business and strategic objectives in Canadian and international markets.

- The Board approved the appointment of Mrs. Shilpa Sharma as Company Secretary & Compliance Officer and Mr. Viranchi Arvindbhai Shah as a Non-Executive Additional (Independent) Director, effective August 26, 2026. - Approved the adoption of the Senores Pharmaceuticals Employee Stock Option Scheme 2026. - Approved the incorporation of a Wholly Owned Subsidiary in Mexico and a Subsidiary Company in Canada for international market expansion.

- Appointments: Mrs. Shilpa Sharma as Company Secretary & Compliance Officer and Mr. Viranchi Arvindbhai Shah as Non-Executive Additional (Independent) Director were approved. - ESOP: The Senores Pharmaceuticals Employee Stock Option Scheme 2026 was approved for 4,72,000 employee stock options. - Expansion: Approved the incorporation of a Wholly Owned Subsidiary in Mexico and a Subsidiary Company in Canada for market expansion.

- On August 26, 2026, the Board appointed Mrs. Shilpa Sharma as Company Secretary and Mr. Viranchi Arvindbhai Shah as Independent Director. - Approved Employee Stock Option Scheme 2026. - The Board also approved incorporating Wholly-Owned Subsidiaries in Mexico and Canada for strategic market expansion.

- Board approved the appointment of Mrs. Shilpa Sharma as Company Secretary & Compliance Officer (KMP) w.e.f. August 26, 2026. - Board approved the appointment of Mr. Viranchi Arvindbhai Shah as Non-Executive Additional Director (Independent Director) w.e.f. August 26, 2026. - Approved the Senores Pharmaceuticals Employee Stock Option Scheme 2026, encompassing 4,72,000 employee stock options. - Approved the proposed incorporation of a Wholly Owned Subsidiary in Mexico for pharmaceutical product supply and distribution, with 100% ownership. - Approved the proposed incorporation of a Subsidiary Company in Canada for pharmaceutical product supply and distribution, with 51% or more shareholding.

- Senores Pharmaceuticals Limited issued a Corporate Guarantee of INR 62 Crores on August 24, 2026. - The guarantee is for credit facilities availed by its subsidiary, Apnar Pharma Private Limited, from ICICI Bank Limited. - The transaction is at arm's length and is disclosed as a Contingent Liability with no other immediate impact on the Company.

- Analyst / Institutional Investor Meetings Schedule - Meeting Date: 25th August 2026 - Meeting Time: 11:00 AM (IST) Onwards - Hosted by: Antique Stock Broking - Mode: Physical at Mumbai

- Senores Pharmaceuticals Limited shareholders passed all resolutions via Postal Ballot, which concluded on August 03, 2026. - This includes approval for Material Related Party Transactions, enhancement of loan/guarantee/security limits, and variation in IPO proceeds utilization. - All 8 resolutions passed with requisite majority.

- FY27 revenue growth guidance of 30-40% YoY and PAT growth guidance of 50-60% YoY, with a similar trajectory expected thereafter. - Long-term revenue target of ₹2,500-₹3,000 crores in 3-4 years. - FY27 Capex plan of ₹100-120 crores for capacity expansion in oral solids and starting an injectable pilot plant, with FY28 run rate of ₹60-75 crores. - Strategic focus on expanding ANDA portfolio (currently 58 approved, 23 commercialized, 35 more in 18-20 months), ramping up Apnar facility utilization (80-90%), and pursuing European PIC/S approval for Chhatral facility by Q2/Q3. - New subsidiaries Zoraya and Amerisyn expected to commence operations around September/October this year. - Emerging market EBITDA margin expected to be 18-20% on a full-year basis, aiming to sustain overall margin profile of 30%+ as a minimum.

- Audio recording of the Earnings Conference Call held on July 27, 2026, for the quarter ended June 30, 2026, is now available on the company's website (https://senorespharma.com/investor-meet/). - No Unpublished Price Sensitive Information was shared during the call.

- Consolidated Revenue ₹180 Crs vs ₹132.6 Crs (▲36% YoY) - EBITDA ₹54 Crs vs ₹28.9 Crs (▲87% YoY) - PAT ₹31 Crs vs ₹19.9 Crs (▲56% YoY) - EBITDA Margin ~30.0% vs ~21.8% (▲800bps)

- Consolidated Revenue ₹180.21Cr vs ₹132.56Cr (▲36% YoY) - EBITDA ₹56.57Cr vs ₹37.52Cr (▲51% YoY) - PAT ₹30.45Cr vs ₹21.18Cr (▲44% YoY) - EBITDA Margin 31.39% vs 28.30% (▲309bps) - Board approved the appointment of Ms. Anjali Shah as Assistant Vice President-Finance and Senior Management Personnel (SMP) with effect from July 27, 2026.

- Consolidated Revenue ₹180.21 Cr vs ₹132.56 Cr (▲35.94% YoY) - EBITDA ₹53.76 Cr vs ₹28.73 Cr (▲87.12% YoY) - PAT ₹30.45 Cr vs ₹21.18 Cr (▲43.77% YoY) - EBITDA Margin 29.83% vs 21.67% (▲816bps)

- Consolidated Revenue ₹180.21Cr vs ₹132.56Cr (▲36% YoY) - EBITDA ₹53.76Cr vs ₹28.73Cr (▲87% YoY) - PAT ₹30.45Cr vs ₹21.18Cr (▲44% YoY) - EBITDA Margin 29.83% vs 21.67% (▲816bps) - The Board approved the appointment of Ms. Anjali Shah as Assistant Vice President-Finance (Senior Management Personnel) with effect from July 27, 2026.